Buspirone Hydrochloride
- Product NDC
- 70518-3607
- 11-digit product format
- 705183607
- Labeler code
- 70518
- Product ID
- 70518-3607_f1763bc1-de62-e5ff-e053-2995a90a316f
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Buspirone Hydrochloride
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- REMEDYREPACK INC.
- Application
- ANDA208972
- Marketing category
- ANDA
- Marketing start
- 2023-01-04
- Marketing end
- 0000-00-00
- Substance
- BUSPIRONE HYDROCHLORIDE
- Active strength
- 15 mg/1
- NDC exclude flag
- No
- Listing certified through
- 2024-12-31
- Current FDA listing
- Historical FDA.report record
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded product | product | 70518-3607 | D | Discontinued by firm | 2026-08-03 | ||
| excluded package | package | 70518-3607 | 70518-3607-0 | D | Discontinued by firm | 2026-08-03 | |
| excluded package | package | 70518-3607 | 70518-3607-1 | D | Discontinued by firm | 2026-08-03 |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A208972-001 | BUSPIRONE HYDROCHLORIDE | BUSPIRONE HYDROCHLORIDE | 5MG | TABLET / ORAL | AB | 2019-04-16 | |
| A208972-002 | BUSPIRONE HYDROCHLORIDE | BUSPIRONE HYDROCHLORIDE | 7.5MG | TABLET / ORAL | AB | 2019-04-16 | |
| A208972-003 | BUSPIRONE HYDROCHLORIDE | BUSPIRONE HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2019-04-16 | |
| A208972-004 | BUSPIRONE HYDROCHLORIDE | BUSPIRONE HYDROCHLORIDE | 15MG | TABLET / ORAL | AB | 2019-04-16 | |
| A208972-005 | BUSPIRONE HYDROCHLORIDE | BUSPIRONE HYDROCHLORIDE | 30MG | TABLET / ORAL | AB | 2019-04-16 | |
| A208972-006 | BUSPIRONE HYDROCHLORIDE | BUSPIRONE HYDROCHLORIDE | 2.5MG | TABLET / ORAL | 2026-05-13 | ||
| A208972-007 | BUSPIRONE HYDROCHLORIDE | BUSPIRONE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | 2026-05-13 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A208972-001 | AB |
| A208972-002 | AB |
| A208972-003 | AB |
| A208972-004 | AB |
| A208972-005 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A208972-001 | BUSPIRONE HYDROCHLORIDE | 5MG | TABLET / ORAL | AB | 2019-04-16 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A208972-002 | BUSPIRONE HYDROCHLORIDE | 7.5MG | TABLET / ORAL | AB | 2019-04-16 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A208972-003 | BUSPIRONE HYDROCHLORIDE | 10MG | TABLET / ORAL | AB | 2019-04-16 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A208972-004 | BUSPIRONE HYDROCHLORIDE | 15MG | TABLET / ORAL | AB | 2019-04-16 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A208972-005 | BUSPIRONE HYDROCHLORIDE | 30MG | TABLET / ORAL | AB | 2019-04-16 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A208972-006 | BUSPIRONE HYDROCHLORIDE | 2.5MG | TABLET / ORAL | 2026-05-13 | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | A208972-007 | BUSPIRONE HYDROCHLORIDE | 12.5MG | TABLET / ORAL | 2026-05-13 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A208972-001 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A208972-002 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A208972-003 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A208972-004 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A208972-005 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Buspirone Hydrochloride | BUSPIRONE HYDROCHLORIDE | IPG Pharmaceuticals, Inc | 2c516eec-65d9-4481-8823-ae6b6da84062 | 2026-06-21 | Warnings, Adverse reactions | 208972 ANDA208972 |
| Buspirone Hydrochloride | BUSPIRONE HYDROCHLORIDE | Aphena Pharma Solutions - Tennessee, LLC | 27db85e9-68ef-4d43-a319-4e2ec8dbae05 | 2020-04-09 | Warnings, Adverse reactions | 208972 ANDA208972 |
| Buspirone Hydrochloride | BUSPIRONE HYDROCHLORIDE | Epic Pharma, LLC | 02628a0c-bfdb-4a58-8e48-bcd8ca12d53b | 2019-05-03 | Warnings, Adverse reactions | 208972 ANDA208972 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 70518-3607-0 | 70518360700 | 60 TABLET in 1 BLISTER PACK (70518-3607-0) | 60 tablet | 2023-01-04 | 0000-00-00 | No | No | Current |